Cargando…

Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors

BACKGROUND: The current cancer research strongly focuses on immune therapies, where the PD-1, with its ligands plays an important role. It is known that PD-L1 is frequently up-regulated in a number of different cancers and the relevance of this pathway has been extensively studied and therapeutic ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Schott, Dorothea Sonja, Pizon, Monika, Pachmann, Ulrich, Pachmann, Katharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641167/
https://www.ncbi.nlm.nih.gov/pubmed/29069824
http://dx.doi.org/10.18632/oncotarget.20346
_version_ 1783271175258898432
author Schott, Dorothea Sonja
Pizon, Monika
Pachmann, Ulrich
Pachmann, Katharina
author_facet Schott, Dorothea Sonja
Pizon, Monika
Pachmann, Ulrich
Pachmann, Katharina
author_sort Schott, Dorothea Sonja
collection PubMed
description BACKGROUND: The current cancer research strongly focuses on immune therapies, where the PD-1, with its ligands plays an important role. It is known that PD-L1 is frequently up-regulated in a number of different cancers and the relevance of this pathway has been extensively studied and therapeutic approaches targeting PD-1 and PD-L1 have been developed. We used a non-invasive, real-time biopsy for determining PD-L1 and PD-L2 expression in CETCs of solid cancer patients. METHODS: CETCs were determined from blood of 128 patients suffering from breast (72), prostate (27), colorectal (18) and lung (11) cancer. The number of vital CETCs and the expression of PD-L1 and PD-L2 were investigated using the maintrac(®) method. RESULTS: PD-L1 expressing CETCs were detected in 94.5% of breast, 100% of prostate, 95.4% of colorectal and 82% of lung cancer patients whereas only 75% of breast cancer patients had PD-L2 positive CETCs. In the PD-L1 and PD-L2 expressing patients the cell fraction of PD-L1 positive CETCs is significantly higher than the fraction of PD-L2 positive CETCs (54.6% vs. 28.7%; p<0.001). Breast cancer patients with metastatic disease had significantly more PD-L1 positive CETCs as compared to patients without metastasis (median 75% vs. 61.1%; p<0.05). CONCLUSION: PD-L1 seems to be a major factor in immune evasion and is highly expressed on CETCs regardless of the type of cancer. Monitoring the frequency of PD-L1 positive CETCs could reflect individual patient's response for an anti-PD-1/PD-L1 therapy and may be a promising target of anticancer treatment.
format Online
Article
Text
id pubmed-5641167
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56411672017-10-24 Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors Schott, Dorothea Sonja Pizon, Monika Pachmann, Ulrich Pachmann, Katharina Oncotarget Research Paper BACKGROUND: The current cancer research strongly focuses on immune therapies, where the PD-1, with its ligands plays an important role. It is known that PD-L1 is frequently up-regulated in a number of different cancers and the relevance of this pathway has been extensively studied and therapeutic approaches targeting PD-1 and PD-L1 have been developed. We used a non-invasive, real-time biopsy for determining PD-L1 and PD-L2 expression in CETCs of solid cancer patients. METHODS: CETCs were determined from blood of 128 patients suffering from breast (72), prostate (27), colorectal (18) and lung (11) cancer. The number of vital CETCs and the expression of PD-L1 and PD-L2 were investigated using the maintrac(®) method. RESULTS: PD-L1 expressing CETCs were detected in 94.5% of breast, 100% of prostate, 95.4% of colorectal and 82% of lung cancer patients whereas only 75% of breast cancer patients had PD-L2 positive CETCs. In the PD-L1 and PD-L2 expressing patients the cell fraction of PD-L1 positive CETCs is significantly higher than the fraction of PD-L2 positive CETCs (54.6% vs. 28.7%; p<0.001). Breast cancer patients with metastatic disease had significantly more PD-L1 positive CETCs as compared to patients without metastasis (median 75% vs. 61.1%; p<0.05). CONCLUSION: PD-L1 seems to be a major factor in immune evasion and is highly expressed on CETCs regardless of the type of cancer. Monitoring the frequency of PD-L1 positive CETCs could reflect individual patient's response for an anti-PD-1/PD-L1 therapy and may be a promising target of anticancer treatment. Impact Journals LLC 2017-08-18 /pmc/articles/PMC5641167/ /pubmed/29069824 http://dx.doi.org/10.18632/oncotarget.20346 Text en Copyright: © 2017 Schott et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Schott, Dorothea Sonja
Pizon, Monika
Pachmann, Ulrich
Pachmann, Katharina
Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors
title Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors
title_full Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors
title_fullStr Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors
title_full_unstemmed Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors
title_short Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors
title_sort sensitive detection of pd-l1 expression on circulating epithelial tumor cells (cetcs) could be a potential biomarker to select patients for treatment with pd-1/pd-l1 inhibitors in early and metastatic solid tumors
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641167/
https://www.ncbi.nlm.nih.gov/pubmed/29069824
http://dx.doi.org/10.18632/oncotarget.20346
work_keys_str_mv AT schottdorotheasonja sensitivedetectionofpdl1expressiononcirculatingepithelialtumorcellscetcscouldbeapotentialbiomarkertoselectpatientsfortreatmentwithpd1pdl1inhibitorsinearlyandmetastaticsolidtumors
AT pizonmonika sensitivedetectionofpdl1expressiononcirculatingepithelialtumorcellscetcscouldbeapotentialbiomarkertoselectpatientsfortreatmentwithpd1pdl1inhibitorsinearlyandmetastaticsolidtumors
AT pachmannulrich sensitivedetectionofpdl1expressiononcirculatingepithelialtumorcellscetcscouldbeapotentialbiomarkertoselectpatientsfortreatmentwithpd1pdl1inhibitorsinearlyandmetastaticsolidtumors
AT pachmannkatharina sensitivedetectionofpdl1expressiononcirculatingepithelialtumorcellscetcscouldbeapotentialbiomarkertoselectpatientsfortreatmentwithpd1pdl1inhibitorsinearlyandmetastaticsolidtumors